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Diabetic cardiomyopathy is a leading cause of heart failure. Developing a novel
therapeutic strategy for diabetic cardiomyopathy and characterizing animal models
used for diabetes mellitus (DM) are important. Insulin 2 mutant (Ins2+/−) Akita is a
spontaneous, genetic, mouse model for T1DM, which is relevant to humans. There are
contrasting reports on systolic dysfunction and pathological remodeling (hypertrophy
and fibrosis) in Akita heart. Here, we used magnetic resonance imaging (MRI) approach,
a gold standard reference for evaluating cardiac function, to measure ejection fraction
(indicator of systolic dysfunction) in Akita. Moreover, we performed Wheat Germ
Agglutinin (WGA) and hematoxylin and Eosin stainings to determine cardiac hypertrophy,
and Masson’s Trichrome and picrosirius red stainings to determine cardiac fibrosis
in Akita. MiR-133a, an anti-hypertrophy and anti-fibrosis miRNA, is downregulated
in Akita heart. We determined if miR-133a mimic treatment could mitigate systolic
dysfunction and remodeling in Akita heart. Our MRI results revealed decreased ejection
fraction in Akita as compared to WT and increased ejection fraction in miR-133a
mimic-treated Akita. We also found that miR-133a mimic treatment mitigates T1DM-
induced cardiac hypertrophy and fibrosis in Akita. We conclude that Akita shows cardiac
hypertrophy, fibrosis and systolic dysfunction and miR-133a mimic treatment to Akita
could ameliorate them.
Keywords: Ins2+/− Akita, miR-133a, cardiac dysfunction, MRI, fibrosis, hypertrophy
INTRODUCTION
Diabetes mellitus (DM) has detrimental effects on multiple organs in our body (Shen et al., 2012),
including the heart (Boudina and Abel, 2007). DM causes diabetic cardiomyopathy (DCM), a heart
muscle disease independent of coronary artery disease, hypertension, or valvular disease, which
leads to cardiac dysfunction (Rubler et al., 1972). DCM and cardiac dysfunction can be evaluated
by different methods including echocardiography (Bugger et al., 2008; Basu et al., 2009; Mishra
et al., 2010b; Kesherwani et al., 2015; Negishi, 2018), pressure-volume loop (Mishra et al., 2010a;
Kesherwani et al., 2017) and magnetic resonance imaging (MRI) (Heijman et al., 2007; La Gerche
et al., 2013). Echocardiography is a non-invasivemethod that utilizes ultrasound tomeasuresmitral
flow and cardiac dimension. A limitation to echocardiography is manual variability especially
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in positioning echocardiographic probe and/or analyses of
cardiac parameters. Pressure-volume loop is widely used for
assessing hemodynamic changes in the heart. In this method,
a probe is inserted into the left ventricular space of the heart
without touching the ventricular wall and pressure–volume
relationship is recorded during contraction-relaxation cycle of
the heart. A major limitation of this method is its invasive nature.
MRI uses magnetic field to generate radio-frequency signals from
the hydrogen atoms of the tissue that minimizes manual errors
(Sun et al., 2017). MRI is a non-invasive method with least
manual variability, thus considered as a gold standard reference
for evaluating cardiac function (La Gerche et al., 2013).
Previous echocardiography and pressure-volume loop- based
studies demonstrate cardiac dysfunction in T1DM (reduced
insulin secretion) and T2DM (insulin resistance) hearts (Boudina
and Abel, 2007; Jia et al., 2018; Negishi, 2018). Although T2DM
is more prevalent than T1DM, the latter could have more severe
impact on cardiac pathology due to high fluctuations in the
blood glucose levels (Boudina and Abel, 2007; Chavali et al.,
2013). Ins2+/− Akita is a spontaneous, chronic, non-obese,
genetic mouse model of T1DM where mutation in insulin 2
gene, which is orthologous to human insulin, causes T1DM
(Yoshioka et al., 1997; Wang et al., 1999). It is relevant to
humans because mutation in insulin gene causes T1DM in
humans (Garin et al., 2010). Although there is no controversy
on T1DM phenotype of Akita, there are contrasting reports on
their cardiac pathology and dysfunction. An echocardiography
and tissue Doppler-based study demonstrates an early diastolic
dysfunction with preserves systolic function in 12- and 24-
week Akita (Ins2 WT/C96Y) (Basu et al., 2009). Another
echocardiography-based study shows no significant change in
cardiac parameters in 20-, 36-, and 54-week Akita, except
the reduced left ventricular developed pressure in 24-week
Akita that suggests a modest left ventricular dysfunction
(Bugger et al., 2008). A speckle-tracking-based study reveals
abnormal cardiac deformation in 12-week Akita (Zhou et al.,
2018). Hemodynamic study using pressure-volume loop shows
reduced ± dp/dt and ejection fraction in 12- to 14-week
Akita (Kesherwani et al., 2017). Thus, there is controversy
on cardiac dysfunction in Akita. Although MRI is a better
method for evaluating cardiac dysfunction (La Gerche et al.,
2013), to our knowledge, no MRI study has been done so
far to evaluate cardiac dysfunction in Akita. Thus, the focus
of our present study is to measure cardiac dysfunction in
Akita using MRI. Akita develops hyperglycemia at 4-week and
becomes robust hyperglycemic at 8–10 weeks (blood glucose
level >500 mg/dL). Because DM at initial stage develops
diastolic dysfunction and at advanced stage develops systolic
dysfunction (Boudina and Abel, 2007), we sought to determine
systolic dysfunction in 24-week Akita by measuring ejection
fraction.
In addition to cardiac dysfunction, there is controversy on
pathological cardiac remodeling in Akita. Hypertrophy and
fibrosis contributes to pathological remodeling in the heart.
A report on Akita heart shows no hypertrophy and fibrosis, even
with elevated cardiac levels of β-myosin heavy chain, a molecular
marker of hypertrophy (Basu et al., 2009). In contrast, other
reports demonstrate increased cardiac hypertrophy (Chavali
et al., 2014; Nandi et al., 2016) and fibrosis (Mishra et al., 2010b;
Kesherwani et al., 2017) in Akita. In streptozotocin-induced
T1DM, another T1DM model system, shows increased cardiac
hypertrophy (Feng et al., 2010) and fibrosis (Chen et al.,
2014). Other clinical and animal-based studies show pathological
remodeling in diabetic hearts (Chavali et al., 2013; Jia et al., 2018;
Negishi, 2018). Thus, there is a controversy on whether Akita
heart shows hypertrophy and fibrosis. To resolve the controversy,
we aim to measure cardiac hypertrophy and fibrosis in 24-week
Akita.
Diabetes mellitus leads to heart failure (Boudina and Abel,
2007; Jia et al., 2018; Negishi, 2018). Thus, developing a
novel therapeutic strategy for DCM is translationally valuable.
MicroRNAs (miRNAs) are a class of tiny, non-coding, regulatory
RNAs (Bartel, 2004). They are a promising therapeutic candidate
for cardiovascular diseases (Mishra et al., 2009a). There are
more than 800 miRNAs present in the human heart, where
miR-133a is the most abundant miRNA (Leptidis et al., 2013).
MiR-133a protects the heart against pathological remodeling by
inhibiting hypertrophy (Care et al., 2007; Feng et al., 2010) and
fibrosis (Matkovich et al., 2010; Chen et al., 2014). Notably,
miR-133a is downregulated in the diabetic hearts of humans
(Nandi et al., 2015) and rodents (Feng et al., 2010; Chavali et al.,
2014; Nandi et al., 2016). Interestingly, overexpression of miR-
133a mitigates cardiac hypertrophy (Nandi et al., 2016), fibrosis
(Chen et al., 2014), and contractile dysfunction (Nandi et al.,
2016) in different rodent models of diabetes. However, the role
of miR-133a mimic in amelioration of cardiac remodeling and
systolic dysfunction in Akita is unclear. In the present study, we
aim to determine if miR-133a mimic treatment could ameliorate
pathological cardiac remodeling and systolic dysfunction in
Akita.
MATERIALS AND METHODS
Animal Experiments
We procured Ins2+/− Akita (C57BL background) mice from
The Jackson Laboratory (Bar Harbor, ME, United States) and
bred them in the animal facility of the University of Nebraska
Medical Center. We used 12-week male Akita and its sibling
normoglycemic Ins2+/+ WT for experiments. Because miR-
133a is reduced in Akita heart (Chavali et al., 2014), we treated
Akita with miR-133a mimic. We packaged miR-133a mimic or
scrambled miRNA (control) into lentivirus (Nandi et al., 2016)
and administered 106 virus particles/mice/one-time through tail
vein injection. These mice were kept in the animal facility for
12-weeks. We performed MRI to measure cardiac dysfunction
of WT, Akita, Akita treated with Lenti-miR-133a (Akita+miR)
or Lenti-scrambled miRNA (Akita+scm) after 12-weeks (age of
mice 24-week), and sacrificed them to collect the heart tissue
for histological and molecular analyses (Figure 1). The breeding
and experimental protocols were approved by the Institutional
Animal Care and Use Committee and the Institutional Biosafety
Committee of the University of Nebraska Medical Center.
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FIGURE 1 | Schematic showing treatment regimen of Akita. (A) Lenti-miR-133a was created by packaging miR-133a mimic with lentivirus protein in 293FT cells and
they were injected into Akita mice at the age of 12 weeks. (B) Lenti-scrambled was created in the same manner as Lenti-miR-133a except for replacing miR-133a
mimic with scrambled miRNA. They were treated to Akita in the same manner as Lenti-miR-133a. (C) Flow schematic showing the timeline for genotyping, mice
treatment, performance of cardiac-MRI, and sacrifice. WT, N = 5; Akita, N = 5; Akita+miR-133a, N = 5; and Akita+scm, N = 5.
Lentivirus Packaging and Treatment
The detailed method of lentivirus packaging and delivery into
mice are described in Supplementary Material and in our
previous publication (Nandi et al., 2016). In brief, we transfected
293FT cells with GFP-tagged miR-133a or GFP-tagged scrambled
miRNA vectors (cat # MmiR3445-MR03 and cat# CmiR0001-
MR03, respectively, GeneCopoeia, Rockville, MD, United States)
along with lentivirus protein coding genes VSVG, RSV-REV, and
pMDLg/p RRE to generate miR-133a mimic-packaged (Lenti-
miR-133a) or scrambled miRNA-packaged (Lenti-scrambled)
lentivirus. We precipitated lentivirus by polyethylene glycol and
through centrifugation, and calculated virus titer by infecting
293FT cells with different volumes of aliquoted virus.
Cardiac Magnetic Resonance
Imaging (MRI)
We anesthetized mouse with inhalation anesthesia (1.5%
isoflurane in 100% O2), placed the mouse in a Plexiglas holder,
and then placed in a whole-body-quadrature-birdcage coil for
imaging. The breathing rate of the anesthetized mouse was
monitored continuously using an SA Instruments (Stony Brook,
NY, United States) model 1025 small animal monitoring and
gating system. MRI studies were done on a 7 Tesla MRI scanner
(Bruker BioSpin 70/21, Ettlingen, Germany). The MR system
was run with ParaVision 5.1 including the IntraGate software
for sequence acquisition and reconstruction. Studies begin with
a 3-plane gradient recalled localizer (TR = 15 ms TE = 1.69 ms
NA = 15, total imaging time = 30 s) to center the animal in
the magnet and coil. After localization and system shimming,
the following image types were obtained on each mouse. A T1
weighted coronal RARE scan (TR = 1300 ms, TE = 9 ms, RARE
factor = 4, 256 × 192 acquisition matrix, 40 mm FOV, 9 slices
NA = 2, total imaging time = 2.08 min) for anatomical reference
and to locate the cardiac muscle. T1 weighted single slice double
oblique Intragate FLASH1 (256 × 256 matrix, 30 mm FOV,
TE = 2.168ms, TR = 8.5ms, 200 images for a total imaging time of
7.68 min). Cardiac and respiratory compensates scans were then
acquired to generate images with 10 phases through the cardiac
cycle (Heijman et al., 2007).
2D Cardiac Performance Analyses of
MRI
Left ventricular (LV) function was assessed with steady state
free-precession cine MR pulse sequence in the long-axis plane.
CMR images were analyzed offline by a single observer (QS)
using 2D cardiac performance analysis-MR (version 1.2.3.13,
Edisonstrasse, Germany). The horizontal long axis was used for
CMR-feature tracking analysis to derive LV longitudinal strain.
The LV endocardial surfaces were manually traced by a point-
and-click approach when the chamber was at its maximum
size. The software, creating a region of interest, automatically
generated an epicardial surface tracing. The region of interest
was adjusted and automated tracking algorithm was applied.
Tracking performance was reviewed to ensure accurate tracking
of the ventricular myocardium, and when necessary, manual
adjustments were made before the algorithm was reapplied. The
software provided segmental and global values for strain in the
long-axis view, as well as global ejection fraction.
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RNA Extraction and miRNA Assay
The detailed protocols for RNA extraction and miRNA assay
are described in our previous publications (Mishra et al., 2009b;
Chavali et al., 2014; Nandi et al., 2016). In brief, we used
mirVana miRNA Isolation Kit (cat # AM1560, Life Technologies,
United States) to extract miRNA. After confirming good quality
RNA by NanoDrop 2000c (Thermo Fisher Scientific, Waltham,
MA, United States), we made complimentary DNA using
TaqMan R© MicroRNA reverse transcription kit (cat # 4366597,
Life Technologies, United States), and then amplified miRNA by
qPCR using Taqman primers specific for miR-133a (Assay ID-
002246, Life Technologies, United States) and U6 SnRNA (assay
ID: 001973, Life Technologies, United States). U6 snRNA was
endogenous control for miR-133a assay (Figure 5). We used Bio-
Rad CFX qPCR instrument and analyzed the results by Bio-Rad
CFXManager3.0 software (Bio-Rad Laboratories, United States).
WGA Staining
We performed standard wheat germ agglutinin (WGA) staining
on 5 µm cryosections of the heart from the four groups of mice:
WT, Akita, Akita treated withmiR-133amimic (Akita+miR), and
Akita treated with scrambled miRNA (Akita+scm). The details
of WGA staining are elaborated in our previous publication.
In brief, we prepared heart cryosections by using CryoStar
NX50 (Thermo Fisher Scientific, Waltham, MA, United States)
and fixed them in 4% paraformaldehyde. We washed them
with phosphate buffered saline (PBS) and then incubated them
with 5 µg/ml of WGA (cat # W834, Thermo Fisher Scientific,
Waltham, MA, United States) for 10 min at room temperature.
They were then washed, mounted with coverslip, and observed
under a fluorescence microscope (EVOS, Life Technologies,
United States). Representative WGA stainings of the heart from
the four groups are presented in Figures 3A, 7A. We measured
mean cardiomyocyte diameter (µm) in high magnification (40×)
image. We randomly selected five areas (within the black open
circle in Figures 3C, 7C) in the left ventricle and scored total
50 cells/per mouse from the five areas (10 cells/area). The
mean cardiomyocytes diameter was quantified to determine
cardiomyocytes hypertrophy.
Hematoxylin–Eosin Staining
Cryosections of left ventricle from the above-mentioned four
groups of mice were fixed in 4% paraformaldehyde. The
hematoxylin and eosin (H&E) staining was performed on these
fixed sections following the kit protocol (cat # HAE-1, ScyTeK
Laboratories Inc., Logan, UT, United States) and observed under
a bright-field microscope (Leica Microsystems, Buffalo Grove, IL,
United States). The images were analyzed by the Image Pro7.0
software.
Picrosirius Red Staining
To determine cardiac fibrosis, we performed picrosirius red
staining. In brief, 10% formalin fixed left-ventricular paraffin
sections (5 µm) were processed for picrosirius red staining. The
reagents were Direct Red 80 (cat # 365548) and picric acid (cat #
P6744-1GA) from Sigma Aldrich, St. Louis, MO, United States
and glacial acetic acid (cat # A38-500) from Thermo Fisher
Scientific, Waltham, MA, United States. We used standard kit
protocol for this staining. We used the Tissue Core facility of the
University of Nebraska Medical Center for this staining.
Masson’s Trichrome Staining
To corroborate the picrosirius red results, we used Masson’s
Trichrome staining where the blue color represents collagen
(Figures 4B, 8B). The details of this protocol are described in our
previous publication (Kesherwani et al., 2017). We followed the
kit protocol (Masson’s Trichrome kit, cat # 87019, Thermo Fisher
Scientific, Waltham, MA, United States) to stain paraffin sections
(5 µm) of the heart. We used bright-field VWR microscope
and Motic Images Plus 2 imaging tool (Motic) for imaging. We
calculated perivascular (PV) and interstitial (INT) fibrosis by
quantifying % blue color pixel/total pixel using Image J software,
NIH. We used the Tissue Core facility of the University of
Nebraska Medical Center for Masson’s Trichrome staining.
Statistical Analyses
We evaluated cardiac dysfunction and histological analyses of
the heart in random order and a blinded fashion. We presented
statistical values as mean ± SD. We used two-tailed, unpaired
Student’s t-test to determine the difference between two groups.
For miR-133a assay, we used one-way ANOVA followed by
Tukey’s multiple comparison test and values are presented as
mean ± SEM. Graph Pad Prism 7 software was used for
statistical analyses. A P-value of <0.05 is considered statistically
significant.
RESULTS
Akita Exhibits Systolic Dysfunction
To determine whether Akita exhibits systolic dysfunction, we
performedMRI onWT and Akita hearts. We scored longitudinal
strain in different parts of the heart (Figure 2A). We found that
myocardial function was less aligned in Akita heart (Figure 2A)
indicating myocardial dysfunction. Moreover, our MRI results
showed reduced ejection fraction in Akita (Figure 2B). The
short-axis view of MRI also supports cardiac dysfunction
(Figure 2C). These findings demonstrate systolic dysfunction in
Akita. Systolic dysfunction may result due to pathological cardiac
remodeling, which was determined by cardiac hypertrophy and
fibrosis.
Akita Shows Cardiac Hypertrophy
To investigate if Akita has cardiac hypertrophy, we performed
WGA staining. WGA stains cell membrane (green) that helps
to trace cardiomyocytes boundary (Figure 3A). We found that
cardiomyocytes size was increased in the left ventricle of Akita
(Figures 3A,B). To support the WGA results, we performed
H&E staining that also shows cardiomyocytes size. The size of
cardiomyocytes was comparatively larger and space between the
cardiomyocytes was less in Akita (Figure 3C). The left ventricle
region for hypertrophy measurement was kept identical in WT
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FIGURE 2 | Measurement of cardiac dysfunction in Akita by MRI. (A) 2D cardiac performance analysis-MR tracking of left ventricle using long-axis MRI. The global
longitudinal strains were recorded. (B) Analyses of cardiac ejection fraction by long-axis MRI. Values are represented as mean ± SD, N = 4–5 per group.
(C) Representatives of short-axis images of the heart from WT and Akita mice. Two-tailed, unpaired Student’s t-test was used for statistical analysis. P < 0.05 is
considered statistically significant.
FIGURE 3 | Measurement of cardiac hypertrophy in Akita. (A) Representative Wheat Germ Agglutinin (WGA) staining of the heart sections. Green color represents
cardiomyocyte boundary and “∗” denotes a typical cardiomyocyte size. (B) Quantification of cardiomyocytes diameter. Values are presented as mean ± SD. N = 3
per group. Total number of cells scored for hypertrophy was 50. A minimum of five different fields of left ventricle was used from each mice. Two-tailed, unpaired
Student’s t-test was used for statistical analysis. P < 0.05 is considered statistically significant. (C) Representative hematoxylin–eosin staining of left ventricular
section. Outlined circles represent the area used for hypertrophic analysis.
and Akita (black open circles) (Figure 3C) and the same area
was used for the WGA staining and for the quantification of
cardiomyocytes area.
Akita Shows Cardiac Fibrosis
Cardiac fibrosis makes the heart stiffer and less compliant.
To determine cardiac fibrosis, we performed picrosirius red
staining. We found increased collagen deposition in picrosirius
red stained Akita heart (Figure 4A), indicating increased cardiac
fibrosis. To corroborate it, we performed Masson’s Trichrome
staining. We observed increased collagen deposition (blue color)
in Akita heart in the perivascular (PV) and the interstitial (INT)
regions (Figure 4B). We quantified the percentage area of fibrosis
in the PV (Figure 4C) and the INT (Figure 4D) regions of the
heart and found that fibrosis was increased in both regions of
Akita heart (Figures 4C,D).
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FIGURE 4 | Measurement of cardiac fibrosis in Akita by picrosirius red and Masson’s Trichrome stainings. (A) Representative images of picrosirius red stained heart
sections (left ventricle region) of WT and Akita mice. (B) Representative images of Masson’s Trichrome stained heart sections of WT and Akita mice. Arrow shows
collagen deposition (blue) in the heart. PV, perivascular area and INT, interstitial area (C,D). Quantification of percentage fibrosis (pixel blue color area/total pixel area)
by Image J in the four groups. Values are presented as mean ± SD. N = 3 per group was randomly selected for the fibrosis analyses. Two-tailed, unpaired Student’s
t-test was used for statistical analysis. P < 0.05 is considered statistically significant.
Altogether, the above findings demonstrate that Akita
exhibits cardiac remodeling (increased hypertrophy
and fibrosis) and systolic dysfunction (reduced ejection
fraction).
MiR-133a Mimic Treatment Increases
Cardiac miR-133a and Ameliorates
Systolic Dysfunction in Akita
To validate that cardiac levels of miR-133a is reduced in Akita
and miR-133a mimic treatment could increase cardiac levels
of miR-133a in Akita, we treated Akita with Lenti-miR-133a
(Figure 1A) or Lenti-scrambled (Figure 1B). We extracted
the heart and measured cardiac levels of miR-133a in the
treated and the untreated groups by individual miR-133a assay
(Figure 1C). We found that cardiac levels of miR-133a
was decreased in Akita (Figure 5). However, Lenti-miR-133a
treatment increased miR-133a level in Akita heart (Figure 5).
These results demonstrate that miR-133a mimic treatment has
potential to increase cardiac levels of miR-133a in Akita. Then,
we sought to determine whether the increased miR-133a in
Akita heart improves systolic dysfunction. We performed cardiac
MRI on miR-133a mimic-treated (Akita+miR) and scrambled
miRNA-treated (Akita+scm) Akita. We found that miR-
133a mimic treatment improved the alignment of myocardial
movement as reflected by the tracing (Figure 6A). Notably,
the ejection fraction of miR-133a mimic-treated Akita was
improved (Figure 6B), which was also supported by the short-
axis view (Figure 6C). These findings demonstrate that miR-
133a mimic treatment could mitigate systolic dysfunction of
Akita.
FIGURE 5 | Relative miR-133a expression by the individual miR-133a assay.
RT-qPCR for miR-133a was performed on the left ventricle tissue of the heart
using U6 snRNA as endogenous control. Akita+miR represents Akita treated
with Lenti-miR-133a, and Akita+scm represents Akita treated with
Lenti-scrambled miRNA. Values are represented as mean ± SEM, N = 3 per
group. One-way ANOVA was used for statistical analysis followed by Tukey’s
multiple comparisons test. P < 0.05 was considered as statistically significant.
MiR-133a Mimic Treatment Mitigates
Pathological Cardiac Remodeling in
Akita
DM-induced pathological remodeling contributes to cardiac
dysfunction (Boudina and Abel, 2007; Chavali et al., 2013)
and cardioprotective miR-133a has an anti-hypertrophy
(Care et al., 2007; Feng et al., 2010) and an anti-fibrotic
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FIGURE 6 | miR-133a mimic treatment improves systolic dysfunction of Akita. (A) 2D cardiac performance analysis-MR tracking of left ventricle using long-axis MRI.
The global longitudinal strains were recorded. (B) Analyses of cardiac percentage ejection fraction by long-axis MRI. (C) Representatives of short-axis and long-axis
images of the heart. Values are represented as mean ± SD, N = 4–5 per group. Two-tailed, unpaired Student’s t-test was used for statistical analysis. P < 0.05 is
considered statistically significant.
(Matkovich et al., 2010; Chen et al., 2014) effects. To determine
if miR-133a mimic treatment mitigates cardiac remodeling in
Akita, we measured cardiac hypertrophy and fibrosis in miR-
133a mimic-treated (Akita+miR) and scrambled miRNA-treated
(Akita+scm) mice. We measured cardiac hypertrophy by WGA
staining that demarcates cell boundary (Nandi et al., 2016) and
H&E staining (Figure 7), and cardiac fibrosis by picrosirius red
and Masson’s Trichrome staining (Figure 8; Kesherwani et al.,
2017). MiR-133a mimic treated-Akita showed decreased cardiac
hypertrophy (Figure 7) and fibrosis (Figure 8) as compared
to the scrambled miRNA-treated Akita (Figures 7, 8). These
results demonstrate that miR-133a mimic treatment mitigates
T1DM-induced cardiac hypertrophy in Akita.
Altogether, these results demonstrate that miR-133a mimic
treatment is cardioprotective to Akita. It alleviates cardiac
remodeling and ameliorates systolic dysfunction in Akita.
DISCUSSION
In the present study, we demonstrate systolic dysfunction
in Akita (Figure 2) using MRI method. MRI is a more
reliable method than echocardiography and hemodynamic
measurement methods (La Gerche et al., 2013). Thus, our MRI-
based study gives strong basis to support cardiac dysfunction
in Akita and resolves the controversy on it. To determine
cardiac remodeling, we used two methods to assess cardiac
hypertrophy and fibrosis. Our results demonstrate increased
hypertrophy (Figure 3) and fibrosis (Figure 4) in Akita heart,
supporting pathological cardiac remodeling in Akita (Mishra
et al., 2010b; Chavali et al., 2014; Nandi et al., 2016; Kesherwani
et al., 2017). In addition, our results demonstrate that miR-
133a mimic treatment increased cardiac levels of miR-133a
(Figure 5) and ameliorates systolic dysfunction (Figure 6)
and pathological remodeling (Figures 7, 8) of Akita. These
findings support the previous reports that miR-133a protects
against T1DM-induced cardiac hypertrophy (Feng et al., 2010)
and fibrosis (Chen et al., 2014). Based on these results, we
conclude that reduced levels of miR-133a (anti-hypertrophy
and anti-fibrosis) in Akita heart may contribute to cardiac
hypertrophy and fibrosis resulting in cardiac dysfunction,
and miR-133a mimic treatment to Akita could ameliorate
T1DM-induced cardiac remodeling and systolic dysfunction
(Figure 9).
Empirical evidences support reduced cardiac miR-133a in
Akita (Chavali et al., 2014) and other models of T1DM (Feng
et al., 2010; Chen et al., 2014). In our previous report, we
have demonstrated that delivery of miR-133a packaged into
lentivirus is able to increase the cardiac levels of miR-133a (Nandi
et al., 2016). Our present results validate decreased levels of
miR-133a in Akita heart (Chavali et al., 2014) and increased
cardiac levels of miR-133a in miR-133a mimic-treated Akita
heart (Nandi et al., 2016; Figure 5). Because miR-133a is largely
transcribed in the heart and skeletal muscle (Liu et al., 2008),
the expression of injected miR-133a mimic should be largely
in these organs. Accordingly, we found ∼6-fold increase in
the cardiac levels of miR-133a in Akita heart after miR-133a
mimic treatment. Recently, we found that miR-133a is present in
the neurons of the periventricular region of the brain (Sharma
et al., 2017), thus we cannot rule out the systemic effects of
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FIGURE 7 | miR-133a mimic treatment mitigates cardiac hypertrophy in Akita. (A) Representative Wheat Germ Agglutinin (WGA) staining of the heart (left ventricle)
sections. Green color represents cardiomyocyte boundary and “∗” denotes a typical cardiomyocyte size. (B) Quantification of cardiomyocytes diameter. Values are
presented as mean ± SD. N = 3 per group. Total number of cells scored for hypertrophy was 50. A minimum of five different fields of left ventricle was used from
each mice. Two-tailed, unpaired Student’s t-test was used for statistical analysis. P < 0.05 is considered statistically significant. (C) Representative
hematoxylin–eosin staining of left ventricular section. Outlined circles represent the area used for hypertrophic analysis.
FIGURE 8 | miR-133a mimic treatment alleviates cardiac fibrosis in Akita (A). Representative images of picrosirius red stained heart sections (left ventricle region) of
Akita treated with miR-133a mimic (Akita+miR) or scrambled miRNA (Akita+scm). (B) Representative images of Masson’s Trichrome staining of the heart sections of
Akita+miR and Akita+scm. Arrow shows the collagen deposition (blue) in the heart. PV, perivascular area; INT, interstitial area (C,D). Quantification of percentage
fibrosis (pixel blue color area/total pixel area) by Image J in the four groups. Values are presented as mean ± SD. N = 3 per group was randomly selected for the
fibrosis analyses. Two-tailed, unpaired Student’s t-test was used for statistical analysis. P < 0.05 is considered statistically significant.
FIGURE 9 | Schematics showing that T1DM decreases the cardiac levels of miR-133a, which induces cardiac hypertrophy and fibrosis and decreases percentage
ejection fraction (% EF) that ultimately results in cardiac dysfunction and heart failure. MiR-133a mimic treatment mitigates T1DM-induced cardiac hypertrophy and
fibrosis, increases EF and ameliorates cardiac dysfunction/heart failure.
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miR-133a mimic treatment in Akita. This is a limitation of
the present study. Future studies with cardiac-specific miR-133a
transgenic mice would explain the specific impact of miR-133a
overexpression in the heart on cardiac dysfunction in T1DM
mice. However, the aim of this study was to determine whether
the decreased miR-133a contributes to cardiac dysfunction in
Akita heart. To that end, our results show decreased ejection
fraction in Akita (Figure 2) suggesting systolic dysfunction in
Akita. We believe that these findings resolve the controversy
on cardiac dysfunction in Akita because MRI is a more reliable
and unbiased measurement of cardiac dysfunction than the
echocardiography and pressure-volume loop studies (La Gerche
et al., 2013). These results also support the previous findings
from echocardiography and pressure-volume loop studies that
showed cardiac dysfunction in Akita (Bugger et al., 2008; Mishra
et al., 2010b; Kesherwani et al., 2017). Moreover, we demonstrate
that miR-133a overexpression could increase ejection fraction in
Akita (Figure 6). Thus, miR-133a mimic could be a promising
therapeutic candidate to ameliorate cardiac dysfunction in Akita
and possibly in other models of T1DM.
To determine how miR-133a improves cardiac dysfunction
in Akita, we aim to evaluate cardiac remodeling by measuring
cardiac hypertrophy and fibrosis. Because miR-133a is an anti-
hypertrophy (Care et al., 2007; Feng et al., 2010) and an anti-
fibrosis (Matkovich et al., 2010; Chen et al., 2014) miRNA and
downregulated in Akita heart (Feng et al., 2010; Chavali et al.,
2014; Nandi et al., 2016), it is presumed that reduced cardiac
levels ofmiR-133amay contribute to cardiac remodeling in Akita.
Our results of WGA (Figures 3A,B) and H&E (Figure 3C) show
increased cardiac hypertrophy in Akita. It is also documented
that β-myosin heavy chain (a hypertrophy marker) (Basu et al.,
2009) andmatrix metalloproteinase-9 (MMP9), a fibrosis marker,
(Mishra et al., 2010b) are increased in Akita heart. However,
a report shows no hypertrophy and fibrosis in Akita hearts
(Basu et al., 2009). One possible reason for discrepancies
in the results for pathological remodeling in Akita could be
strain variation (we used C57BL/6-Ins2 Akita/J, The Jackson
Laboratory stock number 003548) and/or the age (24-week) of
Akita.
MiRNAs play crucial regulatory roles in biological functions
(Bartel, 2004) and have emerged as a promising therapeutic
candidate for cardiovascular diseases (Mishra et al., 2009a;
Shah et al., 2017) and DCM (Mishra et al., 2017; Ghosh
and Katare, 2018; Nandi and Mishra, 2018). Previous studies
from our laboratory focusing on transcriptome analyses of
Akita heart by RNA-seq and microarray (Chavali et al.,
2014) and miRNA microarray (Kesherwani et al., 2017)
revealed several miRNAs that are differentially regulated in
Akita heart. These studies also support that miR-133a is
downregulated in Akita heart. Interestingly, overexpression
of miR-133a in T1DM heart improves cardiac contractility
(Nandi et al., 2016) and mitigates cardiac fibrosis (Chen et al.,
2014). In the present study, we demonstrate that miR-133a
mimic treatment mitigates cardiac hypertrophy (Figure 7)
and fibrosis (Figure 8) in Akita. Altogether, our findings
provide a solid basis to demonstrate pathological remodeling
in the Akita heart (Figures 3, 4) and also miR-133a as a
therapeutic candidate to mitigate cardiac remodeling in Akita
(Figures 7, 8).
Our results from miR-133a mimic-treated Akita mice has
translational value because DM prevalence is increasing around
the world (King et al., 1998; Wild et al., 2004; Arnold et al., 2016)
and it increases the risk of heart failure (Haffner et al., 1998; Fox
et al., 2007; Jia et al., 2018). Clinical trial shows that tight control
of hyperglycemia in diabetic patients could not reduce the risk of
heart failure (Castagno et al., 2011). Thus, the impetus to develop
a novel therapeutic target for DCM is high. DM exacerbates
mortality in patients with coronary disease (Haffner et al., 1998).
Reduced cardiac miR-133a is common in humans heart failure
with coronary artery disease (Barsanti et al., 2015) and with DM
(Nandi et al., 2015). Thus, supplementing miR-133a could be a
cardioprotective strategy to diabetic patients with coronary artery
disease.
There are several critical aspects and limitations of the
present study. First, miR-133a mimic treatment did not change
blood glucose level in Akita (data not shown) suggesting that
the mitigation of cardiac remodeling and improvement in
systolic dysfunction of Akita by miR-133a mimic treatment is
independent of glucose metabolic pathways. Second, the present
study used a chronic model of T1DM (Akita), which may differ
from acute model of T1DM (streptozotocin-induced T1DM).
Thus, more studies on other models of T1DM are required
to generalize the role of miR-133a in T1DM heart. Third, the
study uses mice, and the results obtained from mice may not
necessarily translate into humans. Therefore, further studies
using human samples are required to support the role of miR-
133a in DCM.
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